Drug intelligence / Profile preview

CYAPO913

Development stage: Preclinical
Lead developer: FibroBiologics
Modality: Cell Therapies

Overview

CYAPO913 is an investigational fibroblast-based cell therapy being developed by FibroBiologics for the treatment of diabetes. The therapy utilizes a proprietary platform to create an insulin-producing artificial pancreatic organoid engineered from fibroblasts. Designed with inherent immune resistance, CYAPO913 aims to restore glycemic control by providing a functional source of insulin while potentially minimizing or eliminating the need for systemic immunosuppression usually required for cell transplants. It is currently in the discovery stage of development as part of FibroBiologics' broader regenerative medicine pipeline.

Other names: fibroblast-based insulin-producing artificial pancreatic organoid

Beyond the preview

Go deeper on CYAPO913.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYAPO913.

Explore the full profile